通过来自Gardasil疫苗接种妇女的抗体对HPV16的附着后中和
Patricia M Day1, Cynthia D Thompson2, Erin M Scherer3,4
1Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. pmd@nih.gov.
NPJ vaccines
|November 20, 2025
概括
人类乳头瘤病毒 (HPV) 疫苗提供了强大的抗感染保护. 通过HPV疫苗接种产生的中和抗体可以防止感染,即使在初始病毒附着在细胞后.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 人类乳头瘤病毒 (HPV) 疫苗在预防异位感染方面表现出高效,这表明具有强大而持久的抗体介导免疫力.
- HPV感染过程涉及病毒附着后的长时间内化阶段,为抗体干预提供了潜在的窗口.
研究的目的:
- 综合评估中和抗体的能力,以防止HPV感染后伪病毒附着在细胞.
- 研究抗体中和HPV感染后附着的机制.
主要方法:
- 使用了Gardasil疫苗接种妇女的血清和单克隆抗体.
- 评估了HPV16伪病毒感染在HaCaT细胞中在附着后的不同时间点 (3-18小时) 中的中和.
- 在高血清稀释 (高达250倍) 时检查的抗体活性.
主要成果:
- 观察到HPV16伪病毒感染的几乎完全的附着后中和,即使是血清稀释250倍,活性逐渐降低至18小时.
- 发现了三种不同的附着后中和机制:囊体脱落,囊体在细胞表面保留,以及内部化后快速囊体降解.
结论:
- 通过HPV疫苗接种诱导的中和抗体在病毒附着后预防感染方面非常有效.
- 已确定的附着后中和机制突出显示了HPV疫苗诱导抗体的多方面的抗病毒活性.
更多相关视频
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
11.4K
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
4.1K
相关概念视频
Vaccinations
51.2K
Overview
51.2K
Immune Response Against Viral Pathogens
1.7K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.7K
Cancer Vaccines
936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936
Humoral Immune Responses
83.3K
Overview
83.3K
Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Active versus Passive Immunity
9.9K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
9.9K
